You are here

Journal of Circulating Biomarkers

Journal of Circulating Biomarkers


Editor-in Chief
Prof. Winston Kuo CloudHealth Genomics, Ltd., China
Associate Editor
Hang Hubert Yin University of Colorado Boulder, USA


eISSN: 18494544 | ISSN: 18494544 | Current volume: 7 | Current issue: 1

Journal of Circulating Biomarkers is an international, peer-reviewed, open access scientific journal focusing on all aspects of the rapidly growing field of circulating blood-based biomarkers and diagnostics using circulating protein and lipid markers, circulating tumor cells (CTC), circulating cell-free DNA (cfDNA) and extracellular vesicles, including exosomes, microvesicles, microparticles, ectosomes and apoptotic bodies. Please see the Aims and Scope tab for further information.

This journal is a member of the Committee on Publication Ethics (COPE).

Why publish in Circulating Biomarkers?

  • Expert international Editorial Board
  • Rigorous peer review of your scholarly work
  • Rapid online publication

Open access article processing charge (APC) information

The APC for this journal is currently an introductory rate of $1500 USD discounted from the full rate of $2000. This introductory rate is available for a limited time.

The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.

Submission information

Submit your manuscript today at http://mc.manuscriptcentral.com/jnlcb

Please see the Submission Guidelines tab for more information on how to submit your article to the journal.

Contact

Please direct any queries to Philippa.stevens@sagepub.co.uk

Journal of Circulating Biomarkers is an international, peer-reviewed, open access scientific journal focusing on all aspects of the rapidly growing field of circulating blood-based biomarkers and diagnostics using circulating protein and lipid markers, circulating tumor cells (CTC), circulating cell-free DNA (cfDNA) and extracellular vesicles, including exosomes, microvesicles, microparticles, ectosomes and apoptotic bodies. The journal publishes high-impact articles that deal with all fields related to circulating biomarkers and diagnostics, ranging from basic science to translational and clinical applications. Papers from a wide variety of disciplines are welcome; interdisciplinary studies are especially suitable for this journal.

Included within the scope are a broad array of specialties including (but not limited to) cancer, immunology, neurology, metabolic diseases, cardiovascular medicine, regenerative medicine, nosology, physiology, pathology, technological applications in diagnostics, therapeutics, vaccine, drug delivery, regenerative medicine, drug development and clinical trials. The journal also hosts reviews, perspectives and news on specific topics.

All submitted articles considered suitable for Journal of Circulating Biomarkers are subjected to rigorous peer review to ensure the highest levels of quality. The review process is carried out as quickly as possible to minimize any delays in the online publication of articles.

Submissions are encouraged from all institutions and on all topics related to circulation protein and lipid markers, CTC, cfDNA and extracellular vesicles, including:

  • technical development and clinical application of circulating protein and lipid markers
  • technical advances in isolation, purification and characterization of CTC, cfDNA, exosomes and other extracellular vesicles
  • clinical applications of CTCs, circulating cell free DNA and extracellular vesicles
  • use of CTCs, cfDNA, exosomes and extracellular vesicles in diagnostics and companion diagnostics
  • use of extracellular vesicles in therapeutics delivery, antigen presentation and vaccine development
  • design and production of cell-derived vesicles and synthetic vesicles
  • biogenesis of extracellular vesicles, both in eukaryotic and prokaryotic cells
  • mechanisms of vesicle: cell interactions intercellular signaling
  • intercellular traffic of proteins, nucleic acids and other macromolecules
  • modulation of the extracellular matrix
  • roles of extracellular vesicles in normal physiological processes, including differentiation, development, immunity, tissue repair, stem cell biology, etc.
  • roles of extracellular vesicles in disease, including cancer, neurodegeneration, diabetes, chronic inflammatory diseases, cardiovascular diseases, infectious disease, ageing, etc.
  • virology and bacteriology
  • use of extracellular vesicles in association with other synthetic nanoparticle for different scopes
Associate Editors
Prof. Roger Chammas Universidade de Sao Paulo, Brazil
Dr. Alain Charest Harvard University Medical School, USA
Dr. Clark Chen University of Minnesota Medical Center, USA
Dr. Stefano Fais Istituto Superiore di Sanità (National Institute of Health), Italy
Ionita Ghiran Beth Israel Deaconess Medical Center, USA
Dr. Daniel Haber Massachusetts General Hospital Cancer Center, USA
Dr. Nancy Raab-Traub University of North Carolina School of Medicine, USA
Prof. Lawrence Rajendran University of Zurich, Switzerland
Dr. John Sinden ReNeuron, UK
Dr. Johan Skog Exosome Diagnostics, USA
Dr. David T. Wong University of California-Los Angeles, USA
Dr. Alexander Vlassov Thermo Fisher Scientific, USA
Editorial Board Member
Dr. Leonora Balaj Massachusetts General Hospital, USA
Pauline Carnell-Morris Malvern Instruments Limited, UK
Dr Cesar Castro Massachusetts General Hospital Cancer Center, USA
Chih Chen National Tsing Hua University, Taiwan
Pui-Wah Choi Arbele Ltd, Hong Kong
Dr. Emanuele Cocucci Comprehensive Cancer Center, The Ohio State University, USA
Dr. Utkan Demirci Stanford University, USA
Dr. Dolores Di Vizio Harvard Medical School , USA
Jiang He University of Virginia, USA
Dr. Stefan Holdenrieder University of Bonn, Germany
Dr. Alexander Ivanov Northeastern University, USA
Dr. Hongjun Kang Tulane University, China
Dr. Shlomit Kenigsberg CReATe Fertility Centre, Canada
Dr. Mehmet Kesimer The University of North Carolina at Chapel Hill, USA
Dr Miroslaw Kornek Saarland University, Germany
Prof. Masahiko Kuroda Tokyo Medical University, Japan
Dr. Heedoo Lee Pulmonary Center, Boston University of Medicine, USA
Dr. Marcis Leja University of Latvia, Latvia
Dr. Sai-Kiang Lim Institute of Medical Biology, Singapore
Dr. Aija Line Latvian Biomedical Research and Study Centre, Riga, Latvia
Dr. Jan Lotvall University of Gothenberg, Sweden
Dr. Todd Lowe University of California – Santa Cruz, USA
Dr. Pierre-Yves Mantel University of Fribourg, Switzerland
Dr. David Meckes Florida State University, USA
Dr. Shannon Pendergrast Ymir Genomics Ltd. USA
Dr. Eva Rohde University Hospital Salzburg, Austria
Dr. Shivani Sharma University of California-Los Angeles, USA
Dr. Zacharias Suntres Northern Ontario School of Medicine, Canada
Yaoliang Tang Augusta University, USA
Dr. John C Tigges Beth Israel Deaconess Medical Center, USA
Dr Gareth Willis Boston Children's Hospital, USA
Dr. Matthew J. Wood University of Oxford, UK
Cindy Yamamoto Hitachi Chemical Co. America, Ltd, USA
Hubert Yin University of Colorado Boulder, USA
Dr. Bruce Zetter Harvard Medical School , USA
Prof. Huang-ge Zhang School of Medicine University of Louisville, USA
Dr. Hanyu Zhu Chinese PLA General Hospital, China
  • Directory of Open Access Journals (DOAJ)
  • PubMed Central (PMC)
  •  This Journal is a member of the Committee on Publication Ethics

    Please read the guidelines below then visit the journal’s submission site http://mc.manuscriptcentral.com/jnlcb to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.

    Only manuscripts of sufficient quality that meet the aims and scope of Journal of Circulating Biomarkers will be reviewed.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    1. Open Access
    2. Article processing charge (APC)
    3. Article Types
    4. Editorial policies
      4.1 Peer Review Policy
      4.2 Authorship
      4.3 Acknowledgements
      4.4 Funding
      4.5 Declaration of conflicting interests
      4.6 Research ethics and patient consent
      4.7 Clinical Trials
      4.8 Reporting guidelines
    5. Publishing policies
      5.1 Publication ethics
      5.2 Contributor's publishing agreement
    6. Preparing your manuscript
      6.1 Word processing formats
      6.2 Artwork, figures and other graphics
      6.3 Supplementary material
      6.4 Reference style
      6.5 English language editing services
    7. Submitting your manuscript
      7.1 ORCID
      7.2 Information required for completing your submission
      7.3 Corresponding author contact details
      7.4 Permissions
    8. On acceptance and publication
      8.1 SAGE Production
      8.2 Continuous publication
      8.3 Promoting your article
    9. Further information

     

    1. Open Access

    Journal of Circulating Biomarkers is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.

    For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs.

    Back to top

    2. Article processing charge (APC)

    If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons licence.

    An introductory article processing charge (APC) US$1500 of is discounted from the full rate of US$2000 is available for a limited time.

    *If the paying party is based in the European Union, to comply with European law, value added tax (VAT) must be added to the APC. Providing a VAT registration number will allow an institution to be exempt from paying this tax, except for UK institutions.

    Back to top

    3. Article types

    Research Article
    These are original articles that report on any area of extracellular vesicles, circulating tumor cells, cell-free circulating DNA and circulating protein markers, and can range from relatively brief descriptions of broad importance to in-depth analyses.

    Review Article
    Review articles are summaries of a topic related to extracellular vesicles, circulating tumor cells, cell-free circulating DNA and circulating protein markers. Reviews should be broadly understandable to the research community, and be restricted to data that is already published. Prospective authors must submit a pre-submission inquiry to the Editors-in-Chief, describing the topic and scope of the proposed review, which the Editors-in-Chief may choose to invite or decline.

    Report
    These articles are brief descriptions of technical matters relevant to the field, including description of new techniques and/or concerns about existing techniques. Reports must provide a detailed description of how materials were obtained, provide a step-by step protocol of how they were used, and explain how measurements were made, calculations were performed, and statistical significance was assessed.

    Perspective
    Perspectives present an opinion, hypothesis, or historical account related to extracellular vesicles, circulating tumor cells, cell-free circulating DNA or circulating protein markers. Prospective authors are strongly encouraged to submit a pre-submission inquiry to the Editors-in-Chief that describes the topic and scope of the proposed perspective.

    Meeting Dispatches
    These articles report on scientific conferences in the field and are invited by the Editors-in-Chief.

    Letter to the Editor
    Letters to the Editor should present a timely and concise discussion of important and published scientific topics.

    Research and Review Articles should be 4 to 12 pages in length, including references, whereas other article types may be shorter.

    Back to top

    4. Editorial policies

    4.1 Peer review policy

    Following a preliminary triage to eliminate submissions unsuitable for Journal of Circulating Biomarkers all papers are sent out for review. The covering letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper suitable for publication. If your paper should be considered for fast-track publication, please explain why. The journal’s policy is to have manuscripts reviewed by two expert reviewers.

    Journal of Circulating Biomarkers utilizes a double-blind peer review process in which the reviewer and author’s names and information are withheld from the other. All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Editor-in-Chief who then makes the final decision.

    As part of the submission process you will be asked to provide the names of 2 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:

    • The reviewer should have no prior knowledge of your submission
    • The reviewer should not have recently collaborated with any of the authors
    • Reviewer nominees from the same institution as any of the authors are not permitted

     You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).

     Please note that the Editors are not obliged to invite any recommended/opposed reviewers to assess your manuscript.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.

    4.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

    • Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
    • Drafted the article or revised it critically for important intellectual content,
    • Approved the version to be published,
    • Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship

    4.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    4.3.1 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.

    Please supply any personal acknowledgements separately to the main text to facilitate anonymous peer review.

    4.4 Funding

    Journal of Circulating Biomarkers requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

    4.5 Declaration of conflicting interests

    It is the policy of Journal of Circulating Biomarkers to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.

    For guidance on conflict of interest statements, please see the ICMJE recommendations.

    4.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants

    All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.

    4.7 Clinical trials

    Journal of Circulating Biomarkers conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

    4.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives

    Back to top

    5. Publishing policies

    5.1 Publication ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.

    5.1.1 Plagiarism

    Journal of Circulating Biomarkers and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    5.1.2 Prior publication

    If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

    5.2 Contributor's publishing agreement

    Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement.  Journal of Circulating Biomarkers publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page

    Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.

    Back to top

    6. Preparing your manuscript

    6.1 Word processing formats

    The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    6.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.

    Figures supplied in colour will appear in colour online.

    6.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.

    6.4 Reference style

    Journal of Circulating Biomarkers adheres to the SAGE Vancouver reference style. Please review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.

    If you use EndNote to manage references, you can download the SAGE Vancouver output file here.

    6.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

    Back to top

    7. Submitting your manuscript

    Journal of Circulating Biomarkers is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/jnlcb to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    7.1 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.

    The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.

    If you do not already have an ORCID ID please follow this link to create one or visit our ORCID homepage to learn more.

    7.2 Informtion required for completing your submission

    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

    7.3 Corresponding author contact details

    Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.

    7.4 Permissions

    Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway.

    Back to top

    8. On acceptance and publication

    If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been check for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.

    8.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will made available to the corresponding author via our editing portal SAGE Edit, or by email to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.

    8.2 Online publication

    One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.

    8.3 Promoting your article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos.

    Back to top

    9. Further information

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Journal of Circulating Biomarkers editorial office as follows:

    jcb@sagepub.co.uk.

    Back to top